Double drug attack: new hope for tough Crohn's cases?
NCT ID NCT06520397
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs—upadacitinib and ustekinumab—works better than just increasing the dose of ustekinumab alone for people with Crohn's disease who didn't get enough help from standard treatment. About 214 adults with active Crohn's will be randomly assigned to one of the two treatment groups. The main goal is to see if the combo leads to more people achieving remission (healing of the gut lining) by week 16, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib and ustekinumab
What this could lead to
If successful, this could offer a more effective treatment option for people with Crohn's disease who don't respond well to standard doses of ustekinumab alone.
What could go wrong
This is a Phase 4 trial, but it's still relatively small (214 participants) and early results may not apply to all patients. Combining two powerful drugs also raises the risk of side effects like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wei Wang
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••